Health Care [ 6/12 ] | Pharmaceuticals [ 25/74 ]
NYSE MKT | Common Stock
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China.
The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions.
Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.
In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets.
Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases.
Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks.
It offers its products through distributors, its network of sales offices, and sales representatives.
The company is based in Haikou, the People's Republic of China.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 17, 23 | -0.06 Decreased by -194.00% | - |
| Aug 17, 23 | -0.06 Decreased by -199.00% | - |
| May 18, 23 | -0.06 Decreased by -200.00% | - |
| Mar 31, 23 | -0.20 Decreased by -900.00% | - |
| Nov 18, 22 | -0.02 Increased by 0.00% | - |
| Aug 18, 22 | -0.02 Increased by 0.00% | - |
| May 19, 22 | -0.02 Increased by 0.00% | - |
| Mar 31, 22 | -0.02 Increased by +33.33% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.80 M Decreased by -8.26% | -777.60 K Increased by +66.54% | Decreased by -43.12% Increased by +63.52% |
| Jun 30, 23 | 1.10 M Decreased by -31.94% | -593.03 K Increased by +76.01% | Decreased by -54.02% Increased by +64.76% |
| Mar 31, 23 | 1.96 M Increased by +22.21% | -1.99 M Increased by +25.98% | Decreased by -101.66% Increased by +39.43% |
| Dec 31, 22 | 2.92 M Increased by +1.09% | -1.35 M Increased by +56.04% | Decreased by -46.15% Increased by +56.52% |
| Sep 30, 22 | 1.97 M Decreased by -0.64% | -2.32 M Decreased by -181.09% | Decreased by -118.20% Decreased by -182.91% |
| Jun 30, 22 | 1.61 M Decreased by -33.22% | -2.47 M Decreased by -199.77% | Decreased by -153.27% Decreased by -348.89% |
| Mar 31, 22 | 1.60 M Decreased by -31.99% | -2.69 M Decreased by -250.85% | Decreased by -167.84% Decreased by -415.85% |
| Dec 31, 21 | 2.89 M Decreased by -1.42% | -3.07 M Decreased by -153.61% | Decreased by -106.12% Decreased by -157.27% |